Viking Therapeutics, Inc.
VKTXUnited States
46 filed reports · 328 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
46 reports · Mar 2015 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 35 | 3,873 | Mar 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 11 | 3,147 | Dec 2015 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 29, 2026 | 243 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 153 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 11, 2026 | 592 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 23, 2025 | 153 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 23, 2025 | 108 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 24, 2025 | 118 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 306 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 23, 2024 | 108 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Jul 24, 2024 | 107 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | Apr 25, 2024 | 114 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 7, 2024 | 284 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Oct 25, 2023 | 116 | Open |
Financial data
328 concepts · 7,020 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial328 concepts · 7,020 facts · Dec 2013 to Jul 2026
- Cash and cash equivalents at carrying value62 · Mar 2014 to Jun 2026
- General and administrative expense (US GAAP)62 · Mar 2014 to Jun 2026
- Increase decrease in accounts payable62 · Mar 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets62 · Mar 2014 to Jun 2026
- Net income loss62 · Mar 2014 to Jun 2026
- Operating expenses (US GAAP)62 · Mar 2014 to Jun 2026
- Operating income loss62 · Mar 2014 to Jun 2026
- Other nonoperating income expense62 · Mar 2014 to Jun 2026
- Research and development expense62 · Mar 2014 to Jun 2026
- Revenue62 · Mar 2014 to Jun 2026
- Share based compensation62 · Mar 2014 to Jun 2026
- Comprehensive income net of tax61 · Jun 2014 to Jun 2026
- Interest income expense nonoperating net61 · Jun 2014 to Jun 2026
- Additional paid in capital common stock60 · Dec 2014 to Jun 2026
- Common stock shares issued60 · Dec 2014 to Jun 2026
- Accounts payable current59 · Dec 2014 to Jun 2026
- Assets59 · Dec 2014 to Jun 2026
- Assets current59 · Dec 2014 to Jun 2026
- Common stock par or stated value per share59 · Dec 2014 to Jun 2026
- Common stock shares authorized59 · Dec 2014 to Jun 2026
- Common stock shares outstanding59 · Dec 2014 to Jun 2026
- Common stock value59 · Dec 2014 to Jun 2026
- Liabilities59 · Dec 2014 to Jun 2026
- Liabilities and stockholders equity59 · Dec 2014 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Jul 2025 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2025 Q4Feb 11, 2026
- FY2025 Q3Oct 22, 2025
- FY2025 Q2Jul 23, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.